Currently, endocrine therapy (ET) combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is the standard of care in the first-line setting for patients with HR + /HER2 − advanced breast cancer (ABC) [3]. This evidence concerns the gene CDK4 and breast carcinoma.